A proposal for score assignment to characterize biological processes from mass spectral analysis of serum.

AIR, acute inflammatory response ALK, anaplastic lymphoma kinase ANG, angiogenesis APR, acute phase reaction BRCA1/2, Breast Cancer Gene 1, Breast Cancer Gene 2 Biological scores Biomarker CA, complement activation CI, confidence interval CPH, Cox proportional hazards CV, coefficient of variation ECM, extracellular matrix organization EGFR, epidermal growth factor receptor FDA, US Food and Drug Administration GLY, glycolysis HR, hazard ratio HbA1c, hemoglobin A1c IFN1, interferon type 1 signaling and response IFNg, Interferon γ signaling and response IRn, type n immune response IT, immune tolerance LC MS-MS, liquid chromatography with tandem mass spectrometry MALDI ToF, matrix-assisted laser desorption/ionization time of flight MRM, multiple reaction monitoring MS, mass spectral Mass spectrometry NSCLC, non-small cell lung cancer OS, overall survival PC, principal component PCA, principal component analysis PCn, principal component n PD-1, programmed cell death protein 1 PD-L1, programmed death-ligand 1 Proteomics QC, quality control Serum proteome Set enrichment analysis WH, wound healing m/Z, mass/charge

Journal

Clinical mass spectrometry (Del Mar, Calif.)
ISSN: 2376-9998
Titre abrégé: Clin Mass Spectrom
Pays: Netherlands
ID NLM: 101697500

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 03 09 2019
revised: 01 09 2020
accepted: 02 09 2020
entrez: 25 11 2021
pubmed: 9 9 2020
medline: 9 9 2020
Statut: epublish

Résumé

Most diseases involve a complex interplay between multiple biological processes at the cellular, tissue, organ, and systemic levels. Clinical tests and biomarkers based on the measurement of a single or few analytes may not be able to capture the complexity of a patient's disease. Novel approaches for comprehensively assessing biological processes from easily obtained samples could help in the monitoring, treatment, and understanding of many conditions. We propose a method of creating scores associated with specific biological processes from mass spectral analysis of serum samples. A score for a process of interest is created by: (i) identifying mass spectral features associated with the process using set enrichment analysis methods, and (ii) combining these features into a score using a principal component analysis-based approach. We investigate the creation of scores using cohorts of patients with non-small cell lung cancer, melanoma, and ovarian cancer. Since the circulating proteome is amenable to the study of immune responses, which play a critical role in cancer development and progression, we focus on functions related to the host response to disease. We demonstrate the feasibility of generating scores, their reproducibility, and their associations with clinical outcomes. Once the scores are constructed, only 3 µL of serum is required for the assessment of multiple biological functions from the circulating proteome. These mass spectrometry-based scores could be useful for future multivariate biomarker or test development studies for informing treatment, disease monitoring and improving understanding of the roles of various biological functions in multiple disease settings.

Identifiants

pubmed: 34820522
doi: 10.1016/j.clinms.2020.09.001
pii: S2376-9998(20)30011-8
pmc: PMC8601010
doi:

Types de publication

Journal Article

Langues

eng

Pagination

13-26

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

Joanna Roder, Heinrich Roder, Julia Grigorieva, Lelia Net, Senait Asmellash, Carlos Oliveira, and Krista Meyer are or were employees of Biodesix, Inc. and have or had stock or stock options in Biodesix, Inc. Joanna Roder, Heinrich Roder and Carlos Oliveria are inventors on related patents assigned to Biodesix, Inc. Sabine Kasimir-Bauer, Harvey Pass and Jeffrey Weber declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS One. 2019 Dec 9;14(12):e0226012
pubmed: 31815946
J Immunother Cancer. 2019 Mar 29;7(1):91
pubmed: 30925943
BMC Bioinformatics. 2019 May 17;20(1):257
pubmed: 31101008
Cancer Immunol Immunother. 2011 Mar;60(3):319-26
pubmed: 21267721
PLoS One. 2013 Aug 20;8(8):e72584
pubmed: 23977322
Nat Rev Cancer. 2017 Mar;17(3):199-204
pubmed: 28154374
Lancet Oncol. 2014 Jun;15(7):713-21
pubmed: 24831979
Front Biosci (Landmark Ed). 2014 Jan 01;19:605-18
pubmed: 24389207
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
BMC Bioinformatics. 2019 May 28;20(1):273
pubmed: 31138112
Nat Rev Cancer. 2016 Aug;16(8):525-37
pubmed: 27388699
Semin Cancer Biol. 2012 Feb;22(1):33-40
pubmed: 22210179
Immunol Rev. 2016 Nov;274(1):290-306
pubmed: 27782320
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMC Med Genomics. 2008 Sep 15;1:41
pubmed: 18793429
J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63
pubmed: 25535693
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Sci Rep. 2017 Mar 27;7:45178
pubmed: 28345601
PLoS One. 2010 Dec 07;5(12):e15004
pubmed: 21165148
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
BMC Cancer. 2018 Mar 20;18(1):310
pubmed: 29558888
Clin Chem. 2006 Jul;52(7):1223-37
pubmed: 16644871
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Cancer Immunol Res. 2018 Jan;6(1):79-86
pubmed: 29208646
Mol Cell Proteomics. 2010 Nov;9(11):2529-44
pubmed: 20739354
Clin Cancer Res. 2020 Oct 1;26(19):5188-5197
pubmed: 32631957
Oncology (Williston Park). 2014 Sep;28(9):780-1
pubmed: 25224476
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
BMC Bioinformatics. 2009 Feb 03;10:47
pubmed: 19192285
Gynecol Oncol. 2013 Feb;128(2):252-9
pubmed: 23178277
BMC Bioinformatics. 2012;13 Suppl 16:S13
pubmed: 23176192
N Engl J Med. 2008 May 15;358(20):2107-16
pubmed: 18480203
Diabetes Metab Syndr Obes. 2017 Aug 14;10:345-361
pubmed: 28860833
Front Immunol. 2019 Apr 12;10:774
pubmed: 31031765
J Immunother Cancer. 2016 Nov 15;4:76
pubmed: 27895917

Auteurs

Joanna Roder (J)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Lelia Net (L)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Carlos Oliveira (C)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Krista Meyer (K)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Senait Asmellash (S)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Sabine Kasimir-Bauer (S)

Department of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstrasse 55, 45147 Essen, Germany.

Harvey Pass (H)

Department of Cardiothoracic Surgery, New York University Langone Medical Center, 550 1 Ave, New York, NY 10016, USA.

Jeffrey Weber (J)

Perlmutter Cancer Center at NYU Langone Medical Center, 550 1 Ave, New York, NY 10016, USA.

Heinrich Roder (H)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Julia Grigorieva (J)

Biodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.

Classifications MeSH